PDCD1 and neoplasm: These results verified that NIL-IM-Lip combined with PD-1 mAb showed great antitumour immunotherapy in both hot tumours and cold tumours by remodelling the suppressive TLIME and simultaneously comobilizing T and NK cells in the TLIME.